08:43 AM EDT, 03/27/2026 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said Friday that the US Food and Drug Administration has approved a label update for its needle-free neffy 1 mg treatment, removing the age requirement for pediatric patients.

The company said the updated label allows use of neffy 1 mg in all patients weighing at least 33 lbs., removing a prior requirement for children to be at least four years old.

The FDA also updated labeling to recommend carrying the product in blister packaging or a dedicated carrying case, ARS Pharmaceuticals ( SPRY ) said.